• Loss of $16.4m, up 17.2% from FY2024
• Achieved FDA clearance for Salix Coronary Anatomy platform, launched in US
• Submitted FDA filings for Salix Coronary Plaque and Flow modules

Artrya Limited reported a loss of $16.4m for the financial year ended 30 June 2025, up 17.2% from the prior year's loss of $14.0m. The company focused on the development and commercialisation of its Salix suite of AI-powered software products for the detection and management of coronary artery disease. Key achievements during the year included receiving FDA 510(k) clearance for the Salix Coronary Anatomy platform, enabling Artrya's commercial launch in the US market. The company signed a five-year, $0.6m agreement with Tanner Health for the clinical deployment of the Salix Coronary Anatomy platform, and also collaborated with two additional US health systems to validate the platform. In the Australian market, Artrya partnered with major radiology providers Sonic Healthcare and Lumus Imaging, with both expected to become commercial customers in FY2026. The company also advanced development of the Salix Coronary Plaque and Salix Coronary Flow modules, submitting FDA filings for these additional capabilities. Artrya progressed the design and site engagement for its SAPPHIRE clinical study to evaluate the Salix Plaque Analysis and Plaque Dispersion Score. The company raised a total of $20m through two placements during the year to support its growth initiatives.

Artrya's key priorities for FY2026 are to secure FDA clearance for the Salix Coronary Plaque module in the third quarter of 2025, followed by clearance for the Salix Coronary Flow module in early 2026. The company will focus on integrating its current US and Australian hospital partners and building customer acquisition and commercial revenues, with the large US market remaining Artrya's primary growth opportunity.